Search hospitals > Ontario > LONDON
Novartis Investigative Site
Claim this profileLONDON, Ontario N6A 4G5
Conducts research for Breast Cancer
Conducts research for Cancer
Conducts research for Age-Related Macular Degeneration
Conducts research for Retinal Vein Occlusion
Conducts research for Chronic Urticaria
72 reported clinical trials
0 medical researchers
Summary
Novartis Investigative Site is a medical facility located in LONDON, Ontario. This center is recognized for care of Breast Cancer, Cancer, Age-Related Macular Degeneration, Retinal Vein Occlusion, Chronic Urticaria and other specialties. Novartis Investigative Site is involved with conducting 72 clinical trials across 83 conditions. There are 0 research doctors associated with this hospital, such as .Area of expertise
1Breast Cancer
ER positive
PR positive
HER2 negative
2Cancer
Top PIs
Clinical Trials running at Novartis Investigative Site
Chronic Urticaria
Multiple Sclerosis
Hives
Philadelphia Chromosome
Myeloid Leukemia
Leukemia
Chronic Myelogenous Leukemia
Chronic Myeloid Leukemia
Lupus Nephritis
Nephritis
Long-term Remibrutinib
for Chronic Hives
This trial tests remibrutinib, a medication for adults with chronic hives not helped by standard treatments. It aims to see if remibrutinib can reduce symptoms by blocking signals that cause hives. Remibrutinib is a highly selective, oral medication that has shown promising efficacy and safety in treating chronic spontaneous urticaria.
Recruiting1 award Phase 34 criteria
Remibrutinib
for Hives
The purpose of the core phase of the trial is to assess the efficacy, safety and tolerability of remibrutinib (LOU064) 25 milligrams (mg) twice a day (b.i.d.) over placebo for 24 weeks and in comparison to omalizumab 300 mg every 4 weeks (q4w) for 52 weeks in participants with chronic spontaneous urticaria (CSU) inadequately controlled by H1-antihistamines (H1-AH). The purpose of the open-label extension phase is to assess efficacy, safety and tolerability up to two years for patients treated with remibrutinib and patients transitioned from omalizumab to remibrutinib at Week 52. In the extension phase, treatment will be with remibrutinib only (i.e., no background therapy). The extension phase will also fulfill the Novartis commitment to provide post-trial access to participants of the previous core phase.
Recruiting1 award Phase 37 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Novartis Investigative Site?
Novartis Investigative Site is a medical facility located in LONDON, Ontario. This center is recognized for care of Breast Cancer, Cancer, Age-Related Macular Degeneration, Retinal Vein Occlusion, Chronic Urticaria and other specialties. Novartis Investigative Site is involved with conducting 72 clinical trials across 83 conditions. There are 0 research doctors associated with this hospital, such as .